Literature DB >> 2839979

Gastroduodenal lesions after transcatheter arterial chemo-embolization in patients with hepatocellular carcinoma.

M Hirakawa1, M Iida, K Aoyagi, T Matsui, K Akagi, M Fujishima.   

Abstract

We investigated the incidence and endoscopic features of gastroduodenal lesions which appeared after transcatheter arterial chemo-embolization (TACE), performed 29 times in 25 patients with inoperative hepatocellular carcinoma. The new development or exacerbation of the gastroduodenal lesions after TACE was evident in 13 of the 29 (45%). The side of the lesions ranged from the gastric body to the second portion of the duodenum, and the lesions that developed were multiple ulcers in four, and multiple erosions with white coat in nine. The development of these gastroduodenal lesions may be due to mucosal ischemia caused by embolic materials, the toxic effect of antineoplastic drugs infuse, or to stress. In light of these events, upper gastrointestinal endoscopy should be added to the usual examinations done for patients undergoing TACE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839979

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Nontarget embolization complicating transarterial chemoembolization in a patient with hepatocellular carcinoma.

Authors:  Christopher R Ingraham; Guy E Johnson; Ajit V Nair; Siddharth A Padia
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

2.  Complications of hepatic chemoembolization.

Authors:  Timothy W I Clark
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 3.  Skin Necrosis Resulting from Nontarget Embolization of the Falciform Artery during Transarterial Chemoembolization with Drug-Eluting Beads.

Authors:  Mitchell T Smith; David Thor Johnson; Matthew G Gipson
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

4.  Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases.

Authors:  Ting-Kai Leung; Chi-Ming Lee; Hsin-Chi Chen
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

5.  Fatal septic complication of transcatheter chemoembolization for hepatocellular carcinoma.

Authors:  T Hashimoto; T Mitani; H Nakamura; S Hori; T Kozuka; Y Kobayashi; A Nakata; T Tsujimura
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Sep-Oct       Impact factor: 2.740

6.  Gastric and duodenal ischaemia after transarterial chemoembolisation for hepatocellular carcinoma: an unexpected but significant complication.

Authors:  Sai Pavan Chintalapati; Arpan Patel; Hari Conjeevaram
Journal:  BMJ Case Rep       Date:  2018-02-21

7.  A case of biliopleural fistula in a patient with hepatocellular carcinoma.

Authors:  Jeffrey R Lewis; Helen S Te; Brian Gehlbach; Aytekin Oto; Jennifer Chennat; Smruti R Mohanty
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

8.  Pancreatic tissue damage by transcatheter arterial embolization for hepatoma.

Authors:  K N Khan; K Nakata; M Shima; Y Kusumoto; N Ishii; T Koji; S Nagataki
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

9.  Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients.

Authors:  Jin Wook Chung; Hyo-Cheol Kim; Jung-Hwan Yoon; Hyo-Suk Lee; Hwan Jun Jae; Whal Lee; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2006 Oct-Dec       Impact factor: 3.500

10.  Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings.

Authors:  José I Bilbao; Alba de Martino; Esther de Luis; Lourdes Díaz-Dorronsoro; Alberto Alonso-Burgos; Antonio Martínez de la Cuesta; Bruno Sangro; José A García de Jalón
Journal:  Cardiovasc Intervent Radiol       Date:  2009-05-16       Impact factor: 2.740

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.